SOURCE: Cervel Neurotech

Cervel Neurotech

October 23, 2013 09:15 ET

Cervel Neurotech™ Initiates Multicenter Clinical Study for Treatment Resistant Depression

Proprietary Steerable Technology Capable of Reaching Deeper Brain Areas May Provide Relief of Symptoms for Patients Resistant to Medication

REDWOOD CITY, CA--(Marketwired - Oct 23, 2013) - Cervel Neurotech, Inc. a privately held company dedicated to pioneering faster and longer-lasting non-invasive and non-pharmacologic treatments for depression, pain and other conditions, announced Tuesday that it has initiated a clinical study for patients suffering from treatment resistant depression at seven leading academic and research centers in the United States.

The 80-patient trial, designed as a randomized, sham-controlled, double blind study, intends to establish the safety and efficacy of the Company's proprietary repetitive transcranial magnetic stimulation (rTMS) system. The primary outcome, change in depression severity, will be measured by the Hamilton Rating Scale for Depression, a well-known and clinically validated measurement tool for depression. The study is currently enrolling patients and more information about study participation can be found at www.cervel.com.

"Throughout the world, there are many millions of people suffering from depression for whom medications are either ineffective or intolerable," said Bret Schneider, M.D., founder and chief medical officer of Cervel Neurotech, Inc. "The initiation of this study brings us one step closer to offering these patients an alternative treatment option free from the debilitating side effects of medication therapy."

Certain disorders, such as depression, are thought to occur because of disordered metabolic activity in a network of regions within the brain. Transcranial magnetic stimulation (TMS) involves using pulsed magnetic fields to create small electrical currents that stimulate areas in the brain to restore metabolism. Cervel's proprietary approach uses multiple magnetic fields, generated by coils placed on a patient's scalp, to selectively stimulate both superficial and deeper brain regions.

About Depression
Depression is a mental disorder characterized by loss of interest or pleasure in activities that were previously enjoyable, a decrease in energy, feelings of low self-worth, disturbed sleep or appetite and difficulty in concentrating.(1) Depression often comes with symptoms of anxiety and these problems can become chronic, substantially impairing the ability of an individual to take care of everyday responsibilities. On a global scale, depression affects more than 350 million people and is the leading cause of disability worldwide.(2)

About the Cervel Neurotech System
The key to the Cervel Neurotech System is Magnetic Spatial Summation™ Technology, which adds or subtracts the energy from multiple overlapping fields. The stimuli generated by the multiple coils reach separate but converging neural tracts in the brain to produce effects greater than those produced by single magnetic coil solutions. Equally important is the system's unique ability to steer the direction of the induced current to the desired regions in the brain. Together these attributes enable unique stimulation and regulation of selected deeper brain targets in specific regions in the brain thought to control the symptoms of a variety of disorders. 

About Cervel Neurotech
Cervel Neurotech, Inc., a privately held medical device company based in Redwood City, CA is pioneering a non-invasive, non-system and non-pharmacologic approach for the treatment of psychiatric and neurologic illnesses. This proprietary technology has the potential to improve the quality of life for patients and their families that are suffering from the debilitating effects of depression, addiction and pain, without the side effects or invasiveness of conventional therapies.

(1) Marcus, M. et al. Depression: A Global Public Health Concern. World Health Organization 2012, Department of Mental Health and Substance Abuse. http://www.who.int/mental_health/management/depression/who_paper_depression_wfmh_2012.pdf. Accessed 04.6.2013.

(2) Marcus, M. et al.

Contact Information